AstraZeneca reports Phase 3 success for eneboparatide in hypoparathyroidism following $1.05B Amolyt Pharma acquisition. Drug ...

The second round of Medicare price negotiations is now underway for all 15 selected drugs with signed agreements in place ...

Incyte's povorcitinib meets endpoints in hidradenitis suppurativa trials but shows lower efficacy than expected, lagging ...

Orca Bio on Monday said its T cell therapy, when used in people with certain blood cancers, reduced the risk of treatment ...

Vertanical reports Phase 3 success for VER-01, a non-opioid cannabis-based painkiller for chronic back pain. Drug could be approved in Europe by July, per founder Clemens Fischer.

At the end of Robert F. Kennedy Jr.'s confirmation hearing, Senate HELP Committee Chairman Bill Cassidy (R-LA) raised a ...

GRO Biosciences, a small but ambitious biotech startup attempting to create novel protein drugs from genetically modified ...

Curevo Vaccine raises $110M Series B for shingles vaccine trial extension, adds Moncef Slaoui as board chair and Moderna's ...

Taiho Pharmaceutical to acquire Swiss biotech Araris for $400M upfront, gaining three antibody-drug conjugates. Deal follows ...

AstraZeneca is fine-tuning plans for a Phase 3 study for its B7-H4-targeting ADC after the drug produced encouraging response ...

Boston biotech hC Bioscience shuts down after failed hemophilia A program, CEO Leslie Williams says. Company had raised $40M ...

Avidity Biosciences shared Monday that its RNA drug for people with certain mutations of Duchenne muscular dystrophy ...